Pirtobrutinib and nematabrutinib are orally available, and reversible noncovalent BTK inhibitors that were next to be studied, with pirtobrutinib now gaining approval for relapsed, refractory MCL and CLL. This evidence concerns the gene BTK and mantle cell lymphoma.